Durvalumab (Imfinzi®)

Assessment Status NCPE Assessment Process Complete
Drug Durvalumab
Brand Imfinzi®
Indication For the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC)  in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).
Assessment Process
Rapid review commissioned 29/03/2019
Rapid review completed 29/04/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/05/2019
Pre-submission consultation with Applicant 10/06/2019
Full submission received from Applicant 30/08/2019
Preliminary review sent to Applicant 20/12/2019
NCPE assessment re-commenced 30/01/2020
Factual accuracy sent to Applicant 16/04/2020
NCPE assessment re-commenced 24/04/2020
NCPE assessment completed 07/05/2020
NCPE assessment outcome The NCPE recommends that durvalumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary

The HSE has approved reimbursement following confidential price negotiations February 2021.